The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

The lack of quick and easy tests has until now slowed the roll-out of new Alzheimer’s drugs like Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla.

Hi, it’s Amber in Hong Kong. Across the strait in Taiwan, breakthrough Alzheimer’s drugs are finally becoming available but ...

In April 2025, the European Medicines Agency (EMA) approved Eisai and Biogen’s Leqembi for early-stage Alzheimer’s disease, marking Europe’s first major nod for a disease-modifying Alzheimer ...

Know the steps to take to protect yourself on social media. Watch the video. Help Register Login Login Hi, %{firstName}% Hi, ...

A report found that the world's youngest Alzheimer's patient is actually a 19-year-old boy. He first started showing signs at ...